Company Overview
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Why Investors Should Care
Revenue has grown at a 145.9% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $184.42M (+404.5% YoY); net profit $-6.88M.
- Trailing 12 Months Year-on-year growth — revenue -96.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 145.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 145.89% |
| 1 Year: | -96.10% |
Stock Price Performance
| 1 Year: | +148.01% |
| 6 Months: | +1.67% |
| 3 Months: | -16.59% |
| 1 Month: | +0.30% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross7d ago
- RSI (14)42.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 145.9% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | STOK Stoke Therapeutics, Inc. R2K | 29.91 | -10.46 | $1.86B | 0.00% | -5.71% | -45.58% | 145.89% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00M | 3.23M | 2.90M | 5.15M | -2.48M | 3.31M | 4.22M | 4.83M | 4.89M | 158.57M | 13.82M | 10.63M | 6.23M |
| Operating Income | -1.91M | -3.01M | -3.32M | -4.54M | -6.32M | -8.45M | -9.84M | -11.07M | -11.73M | -13.01M | -13.71M | -14.59M | -16.83M | -22.03M | -22.68M | -24.80M | -25.24M | -27.15M | -24.69M | -33.26M | -27.23M | -28.37M | -29.34M | -30.00M | 111.24M | -27.30M | -43.09M | -53.42M |
| Net Income | -1.91M | -3.01M | -3.32M | -4.28M | -5.74M | -7.82M | -8.60M | -10.16M | -11.04M | -12.96M | -13.68M | -14.56M | -16.79M | -21.97M | -22.60M | -24.65M | -24.65M | -26.11M | -22.55M | -30.65M | -24.54M | -26.37M | -25.70M | -26.43M | 112.88M | -23.48M | -38.35M | -50.00M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.60 | -0.60 | -0.66 | -0.63 | -0.66 | -0.53 | -0.69 | -0.55 | -0.57 | -0.46 | -0.47 | 1.90 | -0.40 | -0.65 | -0.79 |
| R&D Expense | - | 1.89M | 2.23M | - | 4.13M | 6.02M | 6.52M | - | 7.21M | 7.97M | 8.11M | - | 9.91M | 14.10M | 14.36M | 18.31M | 18.36M | 20.11M | 19.63M | 20.55M | 20.27M | 22.37M | 21.14M | 22.20M | 32.68M | 25.86M | 37.70M | 39.67M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 12.40M | 8.78M | 36.55M | 184.42M |
| Operating Income | -12.78M | -35.68M | -53.04M | -86.06M | -104.36M | -114.77M | -101.37M | -20.59M |
| Net Income | -12.52M | -32.33M | -52.24M | -85.81M | -101.07M | -104.70M | -88.98M | -6.88M |
| Diluted EPS | - | - | - | -2.34 | -2.60 | -2.38 | -1.65 | -0.12 |
| R&D Expense | 8.37M | 23.76M | 32.20M | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 107.54M | 228.75M | 297.93M | 238.87M | 256.07M | 228.34M | 271.56M | 418.43M |
| Total Equity | -1.29M | 105.07M | 224.43M | 286.08M | 217.78M | 184.85M | 159.56M | 229.02M | 352.46M |
| Cash & Equivalents | - | 105.40M | 222.47M | 287.31M | 144.90M | 113.56M | 191.44M | 127.98M | 84.22M |
| Total Liabilities | - | 2.47M | 4.32M | 11.85M | 21.09M | 71.22M | 68.78M | 42.53M | 65.98M |
| Current Liabilities | - | 2.47M | 4.10M | 11.43M | 17.14M | 31.39M | 30.82M | 40.06M | 57.88M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.96M | -31.05M | -42.22M | -66.91M | -31.87M | -81.07M | -86.85M | 45.59M |
| Investing Cash Flow | -925.00K | -1.63M | -1.05M | -76.43M | -45.88M | 105.95M | -107.47M | -186.81M |
| Financing Cash Flow | 115.64M | 149.76M | 108.11M | 1.28M | 46.41M | 53.01M | 131.09M | 97.39M |
| Capital Expenditure | -935.00K | -1.64M | -1.05M | -1.20M | -3.96M | -1.62M | -203.00K | -670.00K |
| Free Cash Flow | -11.90M | -32.69M | -43.27M | -68.11M | -35.83M | -82.68M | -87.05M | 44.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | -841.2% | -1,307.2% | -277.3% | -11.2% |
| Net Margin % | - | - | - | - | -814.7% | -1,192.5% | -243.4% | -3.7% |
| ROE % | -11.9% | -14.4% | -18.3% | -39.4% | -54.7% | -65.6% | -38.9% | -2.0% |
| ROCE % | -12.2% | -15.9% | -18.5% | -38.8% | -46.4% | -58.1% | -43.8% | -5.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RTW Investments LP | 9.03% | 5.62M | $166.18M |
| 2 | Blackrock Inc. | 8.65% | 5.39M | $159.15M |
| 3 | FMR, LLC | 8.64% | 5.38M | $159.09M |
| 4 | Lynx1 Capital Management Lp | 7.65% | 4.76M | $140.77M |
| 5 | Redmile Group, LLC | 6.69% | 4.16M | $123.05M |
| 6 | Morgan Stanley | 5.50% | 3.42M | $101.16M |
| 7 | Baker Bros. Advisors, LP | 5.36% | 3.34M | $98.60M |
| 8 | Toronto Dominion Bank | 5.10% | 3.17M | $93.77M |
| 9 | Wellington Management Group, LLP | 4.97% | 3.10M | $91.48M |
| 10 | BVF Inc. | 4.09% | 2.55M | $75.28M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for STOK
Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential - Investing.com
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPcUYyRUZhTy1PQjI3ZzBmdUl5a25QXzhHYlMzbEVGOFd2dUlQTWpvaXFjR1NtQnM4Ni00WjdBZ2NwazdCT0JtakwxZUFpTmh3RmJtdEZXV25QdlNOWEpSZ0cwNXNGUllzdHJOVUI3cWxXTGs2Mk5Eb2R6NWR1ZUFfcEpFSUxNR1BRY2R3SC…
Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNTEF2ZU5mRkp6RGlPeGRqdHBEcE5YbV9Va29EaG5Mal9WU18tWmxWTjd4bGxXTVlZUFlZUlpmWUYyUkEwM1lPMU5naTlibC1CVXRiYVZNTjZLZnFBUVIwa2p3SG1GVnlmR1VidzRobUNVbHBNYjFzR19SMkRwaWtjWTRjYTZESjZDZG5MZE…
Candriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOK - MarketBeat
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxPeDRvN25zNEluWm1JNFhEOHZiLXFvc3diYzM3cXRaLW9vOUJnVDA5MDcwcW52Z2dhXzRwSHNaYmRQUU9rcmlUbUQxLVk5T19fbTZmRVpRb2pFMDBkWmhMbU9zWWY0Q2E0dzZZb2tBckVQUTFTSVFYT2JvLS1FejNFWlV5Zk9WRlRlUEJVOU…
STOK Initiates Coverage On Goldman Sachs -- Price Target Announced at $44 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPSFdkQnNHT1Z2bl9JSE9walJOMTRFU09rb2pSREZvOFlsMzYzMm9Oa3dDUGhid2Qzdm1oSTJUU3gxRkc3T0FXUTlmWjBKZlI3X3BfX28tX3Zub2VKbm04R0xzZ282RnI3Q0R1OFdPbE42YjIyUDJfZDdYRlBHVG5xMFd6Q1JPZkdkbHpUUk…
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOd2pwMXB3eUxNTm1xeGQ0ak9VNWNtbTZUX3o5QmtxcXdNdVQ1ZkhGa0s5aXNlY09UUjJsZEZVYUxlSjNxV3YwVTl3RzhBcWJvNmtTSzZBMmdrYVZHZ2dpS2pEbmgwaUo1akl4V0RHaXVkN284bWU4eE9JMEtUYmUtazBtTTZXcDc1U0VTWj…
Stoke Therapeutics (STOK) CMO sells 7,228 shares in planned 10b5-1 trades - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxONE92d2NtTEhTZFRUOE5leWxFRTNfNURuc2ZUd1pRZHNvMDFvSm9OcW5VanM4MHAxak0xOC1ITGNqU3FTTkozZEo4OVI5ajBXejRSZG95Z0daSnRrTUFTRHhWOFJSRGY2N05ydzNjMDlSRjdQMjRnem5ZQ1NhZFV6Tzk4M3BjdV9GdV9lTj…
STOK — Frequently Asked Questions
What is the current share price of Stoke Therapeutics, Inc. (STOK)?
As of 2026-07-15 16:51 PDT, Stoke Therapeutics, Inc. (STOK) trades at $29.91 on NasdaqGS. Its 52-week range is $11.75 to $38.35.
What is the market capitalisation of STOK?
Stoke Therapeutics, Inc. (STOK) has a market capitalisation of $1.86B on NasdaqGS.
What is the P/E ratio of STOK?
STOK trades at a trailing price-to-earnings (P/E) ratio of -10.46. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 4.66.
What is the return on equity (ROE) of STOK?
STOK has a return on equity (ROE) of -45.58%. Its return on capital employed (ROCE) is -5.71%.
Is STOK a good stock to buy?
This page provides a data-driven analysis of Stoke Therapeutics, Inc. (STOK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.